Akeso, Inc.

OTCPK:AKES.F Stock Report

Market Cap: US$10.0b

Akeso Valuation

Is AKES.F undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

2/6

Valuation Score 2/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of AKES.F when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Discounted Cash Flow
Simply Wall St
US$17.50
Fair Value
35.6% undervalued intrinsic discount
20
Number of Analysts

Below Fair Value: AKES.F ($11.28) is trading below our estimate of fair value ($17.5)

Significantly Below Fair Value: AKES.F is trading below fair value by more than 20%.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for AKES.F?

Key metric: As AKES.F is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for AKES.F. This is calculated by dividing AKES.F's market cap by their current revenue.
What is AKES.F's PS Ratio?
PS Ratio34.1x
SalesCN¥2.12b
Market CapCN¥72.45b

Price to Sales Ratio vs Peers

How does AKES.F's PS Ratio compare to its peers?

The above table shows the PS ratio for AKES.F vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PSEstimated GrowthMarket Cap
Peer Average24.1x
BBIO BridgeBio Pharma
55x42.3%US$7.3b
NBIX Neurocrine Biosciences
4.9x11.3%US$10.9b
ADMA ADMA Biologics
12.9x18.0%US$5.7b
ASND Ascendis Pharma
23.4x35.2%US$10.3b
AKES.F Akeso
34.1x29.4%US$77.8b

Price-To-Sales vs Peers: AKES.F is expensive based on its Price-To-Sales Ratio (34.1x) compared to the peer average (24.1x).

Price to Sales Ratio vs Industry

How does AKES.F's PS Ratio compare vs other companies in the US Biotechs Industry?

147 CompaniesPrice / SalesEstimated GrowthMarket Cap
BIIB Biogen
1.7x-0.9%US$17.85b
INCY Incyte
2.6x3.2%US$12.02b
BMRN BioMarin Pharmaceutical
3.9x7.1%US$11.90b
MRNA Moderna
3x16.7%US$10.77b
AKES.F 34.1xIndustry Avg. 8.1xNo. of Companies147PS01632486480+
147 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Sales vs Industry: AKES.F is expensive based on its Price-To-Sales Ratio (34.1x) compared to the US Biotechs industry average (8.9x).

Price to Sales Ratio vs Fair Ratio

What is AKES.F's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

AKES.F PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio34.1x
Fair PS Ratio14.6x

Price-To-Sales vs Fair Ratio: AKES.F is expensive based on its Price-To-Sales Ratio (34.1x) compared to the estimated Fair Price-To-Sales Ratio (14.6x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst AKES.F forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentUS$11.10
US$13.54
+22.0%
16.0%US$19.53US$8.47n/a20
Apr ’26US$10.28
US$10.84
+5.4%
15.1%US$13.30US$7.37n/a18
Mar ’26US$9.60
US$9.88
+3.0%
16.2%US$13.08US$7.36n/a18
Feb ’26US$7.10
US$9.84
+38.6%
16.5%US$13.14US$7.39n/a18
Jan ’26US$7.00
US$9.69
+38.4%
16.8%US$12.94US$7.34n/a18
Dec ’25US$9.60
US$9.36
-2.5%
15.3%US$13.05US$7.41n/a19
Nov ’25US$8.10
US$9.30
+14.8%
15.0%US$13.13US$7.53n/a20
Oct ’25US$8.89
US$8.50
-4.4%
9.0%US$10.12US$7.09n/a20
Sep ’25US$5.68
US$7.81
+37.5%
10.1%US$8.95US$5.93n/a20
Aug ’25US$5.72
US$7.61
+33.0%
10.1%US$8.82US$5.89n/a20
Jul ’25US$4.62
US$7.59
+64.2%
9.2%US$8.81US$5.99n/a19
Jun ’25US$5.59
US$7.60
+36.0%
9.1%US$8.80US$6.01n/a18
May ’25n/a
US$7.66
0%
8.7%US$8.78US$6.32US$11.0218
Apr ’25n/a
US$7.65
0%
9.3%US$8.78US$6.34US$10.2818
Mar ’25US$5.70
US$7.16
+25.7%
9.0%US$8.43US$6.26US$9.6018
Feb ’25n/a
US$7.09
0%
12.6%US$8.49US$4.60US$7.1018
Jan ’25n/a
US$7.03
0%
11.5%US$8.55US$4.66US$7.0018
Dec ’24n/a
US$7.06
0%
11.7%US$8.52US$4.62US$9.6017
Nov ’24n/a
US$6.86
0%
11.3%US$8.30US$4.60US$8.1017
Oct ’24n/a
US$6.92
0%
11.3%US$8.31US$4.60US$8.8918
Sep ’24n/a
US$6.96
0%
10.9%US$7.85US$4.60US$5.6817
Aug ’24n/a
US$7.05
0%
12.7%US$7.94US$4.09US$5.7217
Jul ’24n/a
US$6.97
0%
13.1%US$7.94US$4.09US$4.6215
Jun ’24n/a
US$7.04
0%
13.0%US$8.06US$3.97US$5.5917
May ’24n/a
US$7.15
0%
12.7%US$8.25US$4.06n/a17
AnalystConsensusTarget
Consensus Narrative from 20 Analysts
US$13.65
Fair Value
17.4% undervalued intrinsic discount
20
Number of Analysts

Analyst Forecast: Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.

Discover undervalued companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/05/06 22:31
End of Day Share Price 2025/05/06 00:00
Earnings2024/12/31
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Akeso, Inc. is covered by 40 analysts. 20 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Sharon ShiBOCI Research Ltd.
Jiangqiao TongBOCI Research Ltd.
Yonglin YanBOCI Research Ltd.